Akoya Biosciences Inc

79 articles with Akoya Biosciences Inc

• Akoya Biosciences Announces Leadership Transition

  3/20/2023

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023.

• Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance

  3/6/2023

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the fourth quarter and full year ending December 31, 2022.

• Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

  2/28/2023

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the appointment of Jennifer Kamocsay as General Counsel.

• Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences

  2/6/2023

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023.

• Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting

  2/1/2023

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that the company will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology (AGBT) Annual Meeting being held in Hollywood, Florida from February 6-9, 2023.

• Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022

  1/8/2023

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022.

• Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications

  1/6/2023

  Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications.

• Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference

  12/28/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference.

• Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day

  12/15/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event.

• Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance

  11/7/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the third quarter ending September 30, 2022.

• Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

  11/7/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced the launch of PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery and validation on the PhenoImager® platforms.

• Akoya to Participate at Three Upcoming Investor Conferences - November 03, 2022

  11/3/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will be participating in three upcoming investor conferences.

• Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022

  10/11/2022

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022.

• Akoya to Participate at Four Upcoming Investor Conferences in September 2022

  8/31/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will be participating in four upcoming investor conferences.

• Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance

  8/8/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the second quarter ending June 30, 2022.

• Akoya to Participate at Two Upcoming Investor Conferences

  7/27/2022

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be participating in two upcoming investor conferences.

• Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022

  7/12/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022.

• Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic

  6/28/2022

  The OncoSignature ® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers.

• Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting

  6/1/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, will present for the first time, data generated using its proprietary RNA chemistry, which enables whole-slide spatial multiomics at single-cell resolution on the PhenoCycler-Fusion system, at the Advances in Genome Biology and Technology conference in Orlando, Florida, from June 6 to 9.

• Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance

  5/5/2022

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the first quarter ending March 31, 2022.